Emilio Bajetta
#167,760
Most Influential Person Now
Emilio Bajetta's AcademicInfluence.com Rankings
Emilio Bajettaengineering Degrees
Engineering
#7500
World Rank
#8876
Historical Rank
Biomedical Engineering
#764
World Rank
#776
Historical Rank

Emilio Bajettaphilosophy Degrees
Philosophy
#9956
World Rank
#13590
Historical Rank
Logic
#6907
World Rank
#8467
Historical Rank

Download Badge
Engineering Philosophy
Emilio Bajetta's Degrees
- PhD Biomedical Engineering University of Milan
- Doctorate Medicine University of Milan
Why Is Emilio Bajetta Influential?
(Suggest an Edit or Addition)Emilio Bajetta's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) (2234)
- A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. (2004) (1787)
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial (2009) (1366)
- Combination chemotherapy as an adjuvant treatment in operable breast cancer. (1976) (1273)
- Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. (2001) (1025)
- Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. (2001) (1002)
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer (1998) (994)
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial (2007) (836)
- Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010) (784)
- Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. (2007) (578)
- Interleukin-12: Biological Properties and Clinical Application (2007) (564)
- Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. (2000) (527)
- First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. (2002) (513)
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. (2012) (471)
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. (2009) (412)
- Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. (2004) (398)
- Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. (2000) (318)
- Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. (2007) (318)
- Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors (1999) (294)
- Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group (1996) (287)
- Activity of sunitinib in patients with advanced neuroendocrine tumors. (2009) (267)
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study (2008) (253)
- CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. (2008) (214)
- Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? (2007) (211)
- Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. (2005) (198)
- Metastatic melanoma: chemotherapy. (2002) (170)
- Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. (1998) (164)
- An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. (2008) (163)
- Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. (2001) (163)
- A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma (1982) (151)
- Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. (2011) (148)
- 5‐fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors (1998) (141)
- Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma (2004) (138)
- Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. (1994) (138)
- Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. (2002) (134)
- Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. (1996) (134)
- Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. (2011) (132)
- Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon‐alpha‐2a: A study by the Italian trials in Medical Oncology Group (1993) (128)
- Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. (2011) (114)
- Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. (2002) (114)
- A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. (1982) (110)
- Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. (2010) (108)
- Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. (2000) (106)
- Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. (2006) (106)
- Are surgical adjuvant trials altering the course of breast cancer? (1978) (104)
- Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. (2008) (100)
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial (2010) (99)
- Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study (2009) (96)
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors (2009) (93)
- Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). (2006) (92)
- Clinical trials with bleomycin in lymphomas and in solid tumors. (1972) (91)
- Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab (2007) (88)
- Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases (2011) (88)
- Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? (2005) (87)
- A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. (1995) (84)
- Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. (1999) (80)
- Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. (1995) (78)
- Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) (2005) (72)
- A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer. (2012) (68)
- Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. (1995) (67)
- Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study (2014) (67)
- Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors (2006) (67)
- Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial (2011) (66)
- Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. (2004) (65)
- The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. (1999) (64)
- Treatment of cancer-related anemia with epoetin alfa: a review. (2004) (61)
- Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. (2013) (58)
- Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. (2014) (58)
- Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. (1999) (58)
- Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. (2010) (57)
- Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. (1999) (57)
- Pathological features as predictors of recurrence after radical resection of gastric cancer (2006) (56)
- Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens (2013) (55)
- Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. (2003) (55)
- Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (53)
- Ten‐year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus (2002) (52)
- Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (2007) (51)
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (2011) (51)
- Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. (2018) (50)
- Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors (2010) (48)
- Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis (2008) (47)
- Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. (2002) (46)
- Clinical use of adriamycin in advanced testicular cancer. (1972) (46)
- Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. (1995) (45)
- A Pilot Safety Study of Capecitabine, A New Oral Fluoropyrimidine, in Patients with Advanced Neoplastic Disease (1996) (44)
- Single-Institution Series of Early-Stage Merkel Cell Carcinoma: Long-Term Outcomes in 95 Patients Managed with Surgery Alone (2009) (44)
- Treatment of carcinoid syndrome with recombinant interferon alpha-2a. (1993) (43)
- The minimal effective exemestane dose for endocrine activity in advanced breast cancer. (1997) (43)
- Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges (2011) (42)
- Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma (2004) (41)
- Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer (2016) (40)
- Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. (1979) (40)
- Neuroendocrine tumors of unknown primary site: Gold dust or misdiagnosed neoplasms? (2011) (39)
- Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. (1975) (39)
- Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study (2007) (38)
- Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma. (1994) (38)
- Sequential pathologic staging of untreated non‐Hodgkin's lymphomas by laparoscopy and laparotomy combined with marrow biopsy (1977) (38)
- A phase II study of mitoxantrone combined with beta‐interferon in unresectable hepatocellular carcinoma (1993) (38)
- Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. (2000) (37)
- A randomized, multicenter prospective trial assessing long‐acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma (2002) (36)
- 4506 ORAL A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma (2007) (36)
- Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. (2006) (36)
- Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT (2014) (35)
- Sorafenib in Hepatocellular Carcinoma (2009) (35)
- Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. (2007) (35)
- Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. (2000) (34)
- Combined modality treatment for stage I-II non-Hodgkin's lymphomas: CVP versus BACOP chemotherapy. (1988) (34)
- Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. (2004) (33)
- Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. (2004) (33)
- Gemcitabine plus vinorelbine as first‐line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial (2000) (32)
- Genitourinary tumors, non-prostate (2012) (31)
- The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels (1997) (31)
- Prospective evaluation of estrogen receptor-beta in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. (2004) (30)
- Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial. (2000) (29)
- Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials (2012) (29)
- Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. (1993) (27)
- Mitoxantrone: An Active Agent in Refractory Non‐Hodgkin's Lymphomas (1988) (27)
- Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. (2013) (26)
- Phase II Study of Interferon α‐2a and Dacarbazine in Advanced Melanoma (1990) (26)
- Pulmonary Carcinoid Tumours: Indolent but Not Benign (2008) (26)
- Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin. (1982) (25)
- The cost of unresectable stage III or stage IV melanoma in Italy (2012) (25)
- Update on the treatment of neuroendocrine tumors (2003) (25)
- Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. (1995) (24)
- Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma (2008) (24)
- Classic Kaposi's Sarcoma: A Review of 90 Cases (1992) (24)
- Herpes zoster-varicella infection in malignant lymphomas. Influence of splenectomy and intensive treatment. (1975) (24)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (24)
- Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (24)
- Combination chemotherapy with DTIC (NSC-45388) in advanced malignant melanoma, soft tissue sarcomas, and Hodgkin's disease. (1976) (23)
- Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis. (2011) (23)
- Bleomycin alone and in Combination with Methotrexate in the Treatment of Carcinoma of the Esophagus. (1974) (23)
- Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. (2012) (22)
- 252 RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) (2009) (22)
- Informal Caregiving Burden in Advanced Non-small Cell Lung Cancer: The HABIT study (2007) (22)
- Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC) (2008) (22)
- Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer. (1994) (21)
- Treatment of relapse of breast cancer after adjuvant systemic therapy--review and guidelines for future research. (1994) (21)
- Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. (2009) (21)
- Treatment of Metastatic Breast Cancer with Cyclophosphamide, Methotrexate, Vincristine and Fluorouracil. (1973) (21)
- Effects of short-term pre-operative tamoxifen on steroid receptor and Ki-67 expression in primary breast cancer: an immunocytochemical study. (1998) (20)
- New trends in the treatment of malignant melanoma. (1978) (20)
- Fine Needle Percutaneous Intratumoral Chemotherapy under Ultrasound Guidance: A Feasibility Study (1986) (20)
- Laparoscopy and laparotomy in staging Hodgkin's and non-Hodgkin's lymphoma. (1976) (20)
- Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients. (1994) (19)
- Salvage Treatment After rInterferon α-2a in Advanced Neuroendocrine Tumors (1993) (19)
- Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. (1992) (18)
- Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study (1999) (18)
- Neuroendocrine Tumors of the Larynx: A Clinical Report and Literature Review (2006) (18)
- A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (2011) (17)
- Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens (2014) (17)
- Primary uterine cervix melanoma resembling malignant peripheral nerve sheath tumor: a case report. (2008) (17)
- The role of somatostatin analogues in the treatment of gastro-enteropancreatic endocrine tumours. (1996) (16)
- Controlled Study with Imidazole Carboxamide (DTIC), DTIC + Bacillus Calmette-Guérin (BCG), and DTIC + Corynebacterium Parvum in Advanced Malignant Melanoma (1984) (16)
- Liver Assessment in Women Receiving Adjuvant CMF Chemotherapy 1 (1981) (16)
- Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update (2017) (16)
- Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. (1995) (16)
- Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. (2008) (16)
- Efficacy of Treatment with Irinotecan and Oxaliplatin Combination in FU-Resistant Metastatic Colorectal Cancer Patients (2004) (16)
- A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors (2018) (16)
- Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. (2003) (16)
- Clinical Update on Palonosetron in the Management of Chemotherapy-Induced Nausea and Vomiting (2008) (15)
- Steroidal aromatase inhibitors in elderly patients. (2000) (15)
- Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma (2007) (15)
- Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. (2015) (15)
- Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma). (1999) (15)
- Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis (2015) (15)
- Induction Chemotherapy With Carboplatin/Paclitaxel Followed by Surgery or Standard Radiotherapy and Concurrent Daily Low-Dose Cisplatin for Locally Advanced Non-Small Cell Lung cancer (NSCLC) (2003) (15)
- Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. (1996) (15)
- FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. (2008) (14)
- Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National Cancer Institute of Milan. (1993) (14)
- Medical Treatment of Neuroendocrine Tumors (1993) (14)
- Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer (1994) (14)
- Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? (2003) (14)
- Hormonal Regulation of MUC1 Expression (1999) (14)
- Single-Agent Chemotherapy with Vinorelbine for Pretreated or Metastatic Squamous Cell Carcinoma of the Esophagus (2001) (14)
- Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases (2017) (13)
- Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. (2010) (13)
- Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma. (1993) (13)
- Aromatase Inhibitors in the Treatment of Postmenopausal Breast Cancer (1999) (13)
- A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group. (1997) (13)
- Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. (1997) (13)
- Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition (2006) (13)
- Bone turnover markers and insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate. (2003) (13)
- Melanoma and other skin tumors (2012) (13)
- Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo‐leucovorin in untreated patients with advanced colorectal carcinoma (1996) (12)
- Unusual aspects of melanoma. Case 2. Regionally advanced nasal cavity melanoma. (2004) (12)
- An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. (1995) (12)
- Pemetrexed in gastric cancer: clinical experience and future perspectives. (2002) (12)
- Efficacy and safety of RAD001 in advanced biliary tract cancer (BTC) patients (pts) progressing after first-line chemotherapy: A phase II study. (2010) (12)
- The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. (2004) (12)
- Capecitabine: Indications and Future Perspectives in the Treatment of Metastatic Colorectal and Breast Cancer (2001) (12)
- Feasibility Study of Biweekly Capecitabine, Oxaliplatin, and Irinotecan in Patients with Untreated Advanced Gastric Cancer (2009) (12)
- Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. (1994) (12)
- Efficacy and tolerability of 4-hydroxyandrostenedione (4-OHA) as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. (1993) (12)
- Clinical Classification and Survival in Chronic Lymphocytic Leukemia (1979) (12)
- Cytarabine and cisplatin in advanced malignant melanoma. (1986) (11)
- In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). (2005) (11)
- Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer (1998) (11)
- Renal Cancer Treatment: A Review of the Literature (2003) (11)
- Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines. (1993) (11)
- Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
- Methotrexate (NSC-740) and bleomycin (NSC-125066) in the treatment of advanced epidermoid carcinoma of the uterine cervix. (1973) (11)
- Merkel Cell Carcinoma after Liver Transplantation: A Case Report (2007) (11)
- Adriamycin plus Bleomycin versus Cyclophosphamide plus Vincristine in Advanced Carcinoma of the Uterine Cervix (1976) (11)
- Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. (2004) (11)
- Safety profile and treatment response of everolimus in different solid tumors: an observational study. (2014) (11)
- Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan. (1980) (11)
- Raltitrexed plus Oxaliplatin in the Treatment of Metastatic Colorectal Cancer (2004) (11)
- Oral Capeci tabine Compared With Intravenous Fluorourac i l Plus Leucovor in in Pat ients With Metastat ic Colorecta l Cancer : Resul ts of a Large Phase III Study (2001) (10)
- The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor. (2019) (10)
- Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors (2022) (10)
- A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma (2001) (10)
- Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan. (1981) (10)
- Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact. (2002) (10)
- A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. (1984) (10)
- Usefulness of Chest and Skeletal Survey to Assess the Time of Relapse in Breast Cancer (1981) (10)
- Integrated Therapeutic Strategies for Anaplastic Thyroid Carcinoma (2003) (9)
- Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients (2009) (9)
- Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer: A Phase II Study (2014) (9)
- Formestane: effective therapy in postmenopausal women with advanced breast cancer. (1994) (9)
- Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer (1995) (9)
- Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients (2002) (9)
- New clinical trials for the treatment of neuroendocrine tumors. (2000) (9)
- A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. (2016) (9)
- Adjuvant treatment for elderly patients with colon cancer. An observational study. (2008) (9)
- The luteinising hormone–releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers (2000) (9)
- Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report (2010) (9)
- Oxaliplatin doublets in non-small cell lung cancer: a literature review. (2008) (9)
- L'imaging radioisotopico dei tumori neuroendocrini. Quale radiofarmaco e quale metodica? (2001) (8)
- A dose‐finding study of lanreotide (A somatostatin analog) in patients with colorectal carcinoma (1996) (8)
- Capecitabine Chemoradiation for Rectal Cancer after Curative Surgery (2006) (8)
- Development of a Rapid and Ultrasensitive RIA Method for Estrogen (E2, E1, E1-S) Determination with Selective Solid Phase Extraction (1997) (8)
- Safety and activity of Capecitabine in elderly patients with advanced breast cancer (2001) (8)
- Erratum: Treatment of carcinoid syndrome with recombinant interferon alpha-2a (Acta Oncologica Volume 32:2 (1993) 235-8) (1993) (8)
- Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT (1999) (8)
- Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma (2008) (8)
- Activity and safety of capecitabine and irinotecan (CPT-11) in association as first line chemotherapy in advanced colorectal cancer (ACRC) (2001) (8)
- Preliminary Phase I Evaluation of Bleomycin, a New Antitumor Antibiotic (1971) (8)
- Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. (2005) (8)
- [Preliminary study of phase I of bleomycin, a new anti-tumor drug]. (1971) (8)
- [Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?]. (2001) (7)
- Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group. (2013) (7)
- Current Treatments of Neuroendocrine Tumors Role of Biotherapy and Chemotherapy (2003) (7)
- Renal Cell Cancer and Sorafenib: Skin Toxicity and Treatment Outcome (2007) (7)
- Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC). (2010) (7)
- Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan. (1973) (7)
- The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study. (1994) (7)
- New perspectives in the treatment of neuroendocrine tumours. (2012) (7)
- Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas. (1985) (6)
- Prospective randomized trial in advanced malignant melanoma with cis‐platinum, vindesine, and etoposide vs. cis‐platinum, vindesine, and lomustine (1985) (6)
- Recombinant-human-erythropoietin (rhuepo) in the treatment of anemia associated with solid tumors with or without bone-marrow infiltration. (1993) (6)
- Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. (1995) (6)
- 837 Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous (SC) interleukin-2 (IL-2) and interferon-alpha-2b (IFN) in metastatic melanoma (2003) (6)
- Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration (2011) (6)
- Hormone therapy in advanced breast carcinoma: present and future trends. (1994) (6)
- An Intensive Treatment with Mitoxantrone and Ifosfamide in Second-Line Therapy of Epithelial Ovarian Cancer (1994) (6)
- Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. (1993) (6)
- Advances in diagnosis and therapy of neuroendocrine tumors (2001) (6)
- FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. (1998) (6)
- Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response? (2007) (6)
- National integration of European standards. (2007) (5)
- Present status and future perspectives of adjuvant treatment of cutaneous malignant melanoma (1983) (5)
- Everolimus with bevacizumab versus interferon alfa-2a plus bevacizumab as first-line therapy in patients with metastatic clear cell renal cell carcinoma. (2010) (5)
- Controlled studies with bleomycin in solid tumors and lymphomas. (1976) (5)
- CVP versus BACOP Chemotherapy Sequentially Combined with Irradiation in Stage I–II Diffuse Non-Hodgkin’s Lymphomas (1985) (5)
- Oral chemotherapy with doxifluridine and folinic acid in biliary tract cancer. (1995) (5)
- Pitfalls in neuroendocrine tumor diagnosis (2009) (5)
- Prostate adenocarcinoma presenting with supraclavicular node enlargement: report of a case. (2008) (5)
- Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinoma. (2014) (4)
- Ovarian Ablation for Premenopausal Early-Stage Breast Cancer: An Update (2000) (4)
- Front line chemotherapy with four different schedules of gemcitabine and carboplatin in stage IV non-small cell lung cancer (NSCLC) (2001) (4)
- Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors (2004) (4)
- Prostate Adenocarcinoma Presenting with Supraclavicular Node Enlargement: Report of a Case (2008) (4)
- 7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial (2009) (4)
- Is there a possible survival benefit to increasing hemoglobin levels with epoetin alfa during chemotherapy (2004) (4)
- Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). (2011) (4)
- Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma. (1990) (4)
- Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma. (2008) (4)
- Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron (2009) (4)
- Pharmacokinetics of Oral Doxifluridine in Patients with Colorectal Cancer (1999) (4)
- From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours (2011) (4)
- Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine (2004) (4)
- Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer (2004) (4)
- In regard to Kagan: The multidisciplinary clinic. Author's reply (2005) (4)
- [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer]. (2001) (4)
- Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes. (2009) (4)
- Adriamycin (ADM) plus bleomycin (BLM) versus CTX plus VCR in advanced carcinoma of the cervix (1974) (4)
- [New strategies in the treatment of esophageal cancer]. (2002) (4)
- Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). (2009) (3)
- Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC). (2010) (3)
- Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology units in Italy. (2007) (3)
- Is It Possible to Optimize the use of Targeted Therapies in the Treatment of Renal Cell Carcinoma? (2010) (3)
- Single-day regimen of palonosetron (PALO) and dexamethasone (DEX) for the prevention of emesis associated with moderately emetogenic chemotherapy (MEC): Subgroup analysis from a randomized phase III trial. (2016) (3)
- Formestane: an effective first-line endocrine treatment for advanced breast cancer (2005) (3)
- Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma. (1993) (3)
- Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer (2011) (3)
- Palliative treatment for elderly patients with colon cancer in ten Italian medical oncology units. (2008) (3)
- [New drugs in the therapy of colorectal cancer]. (2001) (3)
- Efficacy of Epoetin Alfa in a Retrospective Non-stratified Subgroup Analysis of a Breast Cancer Cohort Receiving Non-platinum Chemotherapy (2004) (3)
- Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: Short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA) (2001) (3)
- Epirubicin Plus Medroxyprogesterone as Second‐Line Treatment of Advanced Prostatic Cancer: A Study by the Italian Trials in Medical Oncology Group (1995) (3)
- Adriamycin in Combination and in Combined Treatment Modalities. (1974) (3)
- Adjuvant Oophorectomy versus CMF in Premenopausal Node-Positive Breast Cancer: Long-Term Results of an Experience at the Milan Cancer Institute (2000) (3)
- Second-Generation Aromatase Inhibitors (1995) (3)
- Integrated Treatment with Doxifluridine and Radiotherapy in Recurrent or Primary Unresectable Rectal Cancer. A Feasibility Study (1999) (3)
- 117 Oxaliplatin plus capecitabine in advanced neuroendocrine tumours (NETs): Is the new WHO classification applicable to daily practice? (2003) (3)
- NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study (2008) (3)
- A dose finding study with erlotinib in combination to irinotecan and capecitabine in metastatic colorectal cancer (mCRC) patients. (2006) (3)
- Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results (2008) (3)
- Home treatment with interleukin 2 and beta-interferon in patients with colorectal cancer and hepatocellular carcinoma. (1994) (3)
- Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes (2009) (2)
- Chemotherapy of advanced malignant-melanoma (review). (1994) (2)
- Updated overall survival and time to progression results in NETs treated with everolimus combination with octreotide LAR as first-line treatment. (2014) (2)
- Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. (1997) (2)
- Radiolabeled somatostaitin analogs in the treatment of neuroendocrine tumors: experience of the National Cancer Institute of Milano using high dose of 111In-pentetreotide in metastatic neuroendocrine gastroenteropancreatic tumors. (2003) (2)
- 451 Elderly patients with advanced breast cancer: safety and efficacy of capecitabine (2003) (2)
- Doxifluridine: an active agent in advanced gastrointestinal cancer. (1995) (2)
- ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment versus a 5-FU/LV regimen for radically resecate gastric cancer. Tolerability and feasibility of a randomized study (2010) (2)
- Neuroendocrine tumors (NETs). (2009) (2)
- Differences in activity of mitoxantrone (DHAD) plus ifosfamide (IFO) according to previous platinum-compound (PC) responsiveness in advanced ovarian cancer (AOC). An I.T.M.O. group study (1993) (2)
- Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma (2010) (2)
- Pharmacological therapy of neuroendocrine tumors. (2010) (2)
- Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancer. (1994) (2)
- Erratum: Informal caregiving burden in advance non-small cell lung cancer: The HABIT study (Journal of Thoracic Oncology (2007) 2, 6, (475-480)) (2007) (2)
- Efficacy of octreotide LAR (OCT) in patients (pts) with advanced neuroendocrine tumors (NET) : A post hoc analysis of the placebo (PBO) arm of the phase III RADIANT-2 study with updated survival data (2014) (2)
- Is Irinotecan Plus Docetaxel Useful as Second-Line Therapy in Advanced Non-small Cell Lung Cancer? (2008) (2)
- Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment-naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial. (2013) (2)
- [Adjuvant chemotherapy following liver metastasis resection in neoplasms of the colorectum]. (1996) (1)
- Guidelines to modern treatment of non-Hodgkin's lymphomas. (1987) (1)
- Disodium Pamidronate in the Treatment of Bone Metastases from Breast Cancer (1993) (1)
- Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05) (2022) (1)
- Pemetrexed disodium (Alimta™) with folic acid (FA) in advanced or metastatic gastric cancer (2001) (1)
- Level of circulating endothelial cells as new biomarker in patients with multiple myeloma, treated with bortezomib-pegylated liposomal doxorubicin-dexamethasone combination. (2006) (1)
- 2320 : Patient’s Fantasies and Worries About Radiation Therapy for Prostate Cancer During the Decision Making Phase (2006) (1)
- Management of infections in immunocompromised cancer patients. (1984) (1)
- Vindesine (VDS) in Padua and Milan (1981) (1)
- 9. Pharmacological Therapy of Neuroendocrine Tumors (2010) (1)
- Effects of aromatase complex selective inhibition on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 circulating levels in breast cancer. (1997) (1)
- Systemic treatment of advanced malignant-melanoma (review). (1993) (1)
- Long-Lasting Exceptional Radiological Complete Response after Treatment with Eribulin in a Patient with Triple-Negative Breast Cancer with Liver Involvement (2018) (1)
- 9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study (2009) (1)
- 3056 POSTER Effect of Palonosetron Plus 1-day Dexamethasone (DEX) on the Prevention of Delayed Nausea and Vomiting Due to Moderately Emetogenic Chemotherapy (MEC): a Pooled Analysis of Two Phase III Trials (2011) (1)
- Reversal of Resistance to Doxifluridine and Fluorouracil in Metastatic Colorectal Cancer: The Role of High-Dose Folinic Acid (1992) (1)
- Proof of concept of correlation between progression-free survival (PFS) and overall survival (OS) in treatment-naive patients with advanced renal-cell carcinoma (mRCC): Final results of a randomized phase II study comparing sorafenib plus interleukin-2 (IL-2) versus sorafenib alone: The ROSORC trial (2013) (1)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (1)
- The cost of unresectable stage III or stage IV melanoma in Italy (2012) (1)
- 4-Hydroxyandrostenedione (4-OHA) as first line treatment in postmenopausal patients with advanced breast cancer(ABC) (1993) (1)
- History of Neuroendocrine Neoplasia (2021) (1)
- Well-Differentiated Neuroendocrine Carcinoma of the Lung: A Case Report (1991) (1)
- Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group. (1994) (1)
- An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review (2010) (1)
- Abstract B33: Osteopontin expression is an independent poor prognostic marker in gastric cancer radically resected. Preliminary report of translational study of ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach) study. (2013) (1)
- 6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study (2011) (1)
- New developments in breast cancer research (1991) (1)
- Control of Emesis by a Low Dose of Ondansetron and Dexamethasone (1994) (1)
- 10 Results of the treatment with IL-12 in patients with malignant melanoma (1997) (1)
- A multicentric randomized phase III study to evaluate the equivalence between lanreotide PR 60 mg vs lanreotide Autogel 120 mg in well-differentiated neuroendocrine tumours (NETs). (2004) (1)
- Advanced Breast Cancer in Elderly Patients: Which Drug after Tamoxifen? (2002) (1)
- Biological study of anastrozole in post-menopausal advanced breast cancer (ABC) patients: Effects on bone metabolism and oestrogen suppression (2001) (1)
- Impressive objective response in a patient with extensive metastatic melanoma including the brain. (2007) (1)
- Activity o f E xemestane i n M etastatic B reast C ancer After F ailure o f N onsteroidal A romatase I nhibitors: A P hase I I T rial (2000) (0)
- [Chemotherapy of malignant melanoma]. (1973) (0)
- Biological and clinical evaluation of Lanreotifle ( BIM 23014 ) , a somatostatin analogue , in the treatment of advanced breast cancer (0)
- Chapter 10 – HODGKIN'S DISEASE: AN OVERVIEW AND ABVD STUDIES IN MILAN (1985) (0)
- 6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study (2011) (0)
- Efficacy and Safety of Everolimus Plus Octreotide LAR in Patients With Colorectal Neuroendocrine Tumors (NET): Subgroup Analysis of the Phase III RADIANT-2 Trial: 394 (2011) (0)
- Acute Immune-Mediated Thrombocytopenia Due to Oxaliplatin Administration: A Case Report (2010) (0)
- Efficacy of Octreotide LAR (OCT) in Patients (pts) with Advanced Neuroendocrine Tumors (NET) : A Subgroup Analysis of Phase III RADIANT-2 Study with Updated Overall Survival (OS) (2014) (0)
- A Case Report of Richter's Syndrome with Review of the Literature (1973) (0)
- A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors. (2015) (0)
- Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) (0)
- 5060 Comparable efficacy of low-dose (1,000 mg/m 2 b.i.d.) capecitabine and standard-dose (1,250 mg/m 2 b.i.d.) capecitabine administered for ≥6 weeks in older women with advanced breast cancer (2009) (0)
- Experience of the NCI-Milan with DTIC plus interferon in the treatment of advanced melanoma: 112 (1993) (0)
- c-erbB 2 serum level as prognostic factor in hormonally treated advanced breast cancer patients. (2002) (0)
- O ral C apecitabine C ompared W ith I ntravenous Fluorouracil P lus L eucovorin i n P atients W ith M etastatic Colorectal C ancer: R esults o f a L arge P hase I II S tudy (2001) (0)
- P-456 Gemcitabine (GEM) plus platinum analogues in advanced/metastatic NSCLC: Preliminary results of a randomized phase II three-arm multicentric study (2005) (0)
- Systemic therapy of melanoma (1994) (0)
- A Phase I 1 Study of Mitoxantrone Combined with Beta-Interferon in Unresectable Hepatocellular Carcinoma (2006) (0)
- Evaluation of G-CSF activity given by intramuscolar (I.M.) route in ovarian cancer patients receiving mitoxantrone (DHAD) + ifosfamide (IFO) as second-line (SL) therapy (1993) (0)
- Evolving perspectives on antiproliferative effects of octreotide treatment: the PROMID data (2010) (0)
- Combinational chemotherapy and radiotherapy (2011) (0)
- Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy (Italian Intergroup Adjuvant Chemotherapy of Adenocarcinoma of the Stomach-ITACA-S Trial). (2015) (0)
- O . Group Study on Second-line Treatment in Advanced Epithelial Ovarian Cancer : an Attempt to Identify Clinical and Biological F actors Determining Prognosis (2015) (0)
- Medical treatment and other combination regimens. (2007) (0)
- Four-drug sequential regimen in advanced breast cancer (1987) (0)
- 452 Osteoprotegerin (OPG) and osteopontin (OPN): their usefulness in monitoring the Anastrzole (AN) treated advanced breast cancer (ABC) patients bearing bone metastases (2003) (0)
- Contents Vol. 71, 2006 (2007) (0)
- Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program (2012) (0)
- 705 Doxifluridine in patients with 5-FU resistant colorectal cancer (1995) (0)
- Preliminary Study of the Bacterial Flora and Indications for Antibiotic Therapy in Cancer Patients (1973) (0)
- [Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection]. (1996) (0)
- Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancer. (1995) (0)
- The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group (1997) (0)
- Phase-ii trial of oral doxifluridine plus oral levo-leucovorin in unresectable hepatocellular-carcinoma. (1995) (0)
- [Preliminary study of the bacterial flora and indications for the use of antibiotic therapy in cancer patients]. (1973) (0)
- 27 Colorectal cancer treatment in elderly patients: results of a retrospective analysis addressed to the chiefs of medical oncology divisions in Italy (2006) (0)
- Medical treatment of hepatocarcinoma. (1992) (0)
- Acknowledgement to Reviewers (2016) (0)
- A randomized study with 4-hydroxyandrostenedione (4-OHA) in postmenopausal advanced breast cancer (ABC): Characteristics of responsive patients (1992) (0)
- Everolimus in combination with Octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 5-years update. (2016) (0)
- Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) (2008) (0)
- Could the Safety Profile of Everolimus be Different in Different Cancers? Fondazione IRCCS Istituto Nazionale Tumori (INT) Experience in Renal Cell Carcinoma, Neuroendocrine Tumors (NETS) and Biliary-Tract Cancers (2012) (0)
- Safety and activity of sorafenib in advanced renal cell cancer: A single institution experience (2007) (0)
- Subject Index Vol. 52,1995 (1995) (0)
- Current Studies at the Milan Cancer Institute with Bleomycin-Containing Regimens for Malignant Lymphomas (1982) (0)
- Combined RT-chemotherapy (CVP vs BACOP) in PS I-II diffuse non-Hodgkin's lymphomas (NHL) (1981) (0)
- Multicenter phase II study of pemetrexed and oxaliplatin as first-line therapy in advanced gastric cancer. (2006) (0)
- R01Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update (2015) (0)
- 376 Oral doxifluridine plus leucovorin in elderly patients with advanced breast cancer (1995) (0)
- 6510 Sequential therapy with FOLFIRI followed by docetaxel plus cisplatin: a promising adjuvant chemotherapy in gastric adenocarcinoma. 5-year follow-up results of the I.T.M.O. Group study (2009) (0)
- 719 Doxifluridine in advanced colorectal carcinoma. Parallel multicentre randomized phase II trial (1995) (0)
- P.26 Adjuvant treatment for elderly patients with colon cancer in ten Italian medical oncology units (2007) (0)
- 6137 POSTER Biological Analysis of Phase II Study Evaluating the Activity of Cetuximab Combined to Oxaliplatin and Fluoropirimidine (TEGAFOX-E) as First Line Treatment in Metastatic Colorectal Cancer (mCRC) Pts by the Italian Trials in Medical Oncology (I.T.M.O.) Group (2011) (0)
- The role of tamoxifen (T) in association with chemotherapy in metastatic melanoma (MM): 189 (1993) (0)
- Procopio G,Verzoni E,Bracarda S,Ricci S,Sacco C,Ridolfi L,Porta C,Miceli R,Zilembo N,Bajetta E,Italian Trials in Medical Oncology (ITMO) group Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC (0)
- Subject Index Vol. 71, 2006 (2007) (0)
- 963 Exemestane in postmenopausal patients with advanced breast cancer: A dose-finding study (1995) (0)
- Phase II study of everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 4-year update. (2015) (0)
- Neuroendocrine tumors: Preface (2010) (0)
- Preoperative treatment with paclitaxel and carboplatin in locally advanced non small cell lung cancer (NSCLC): A phase II trial (2000) (0)
- Letrozoleof its Use in Postmenopausal Women with Advanced Breast Cancer (1998) (0)
- 128Resection versus transplantation for liver metastases from neuroendocrine tumors (2000) (0)
- 9034 Medical treatment choices of over 1000 Italian patients affected by stage IIIB-IV NSCLC in routine clinical practice: results from the observational "SUN" (Survey on the lUng cancer maNagement) study on behalf of SUN study Group (2009) (0)
- Erratum: Safety profile and treatment response of everolimus in different solid tumors: An observational study (Future Oncology (2014) 10:9 (1611-1617)) (2014) (0)
- 1323 mTOR expression in gastrointestinal (GI) tract poorly differentiated endocrine carcinoma (PDEC) (2009) (0)
- Adriamycin Used in Combination with Conventional Agents in the Treatment of Solid Tumors (1975) (0)
- An Unusually Large Pleural Mesothelioma with an Outstanding Clinical Response and Long Lasting Survival: A Case Report and Literature Review (2010) (0)
- Effect of age on treatment outcome to palonosetron (PALO) plus 1-day dexamethasone (DEX) for the prevention of nausea and vomiting in women receiving anthracycline plus cyclophosphamide (AC)-based chemotherapy: A meta-analysis of two phase III trials. (2011) (0)
- [Lateral radiographic projection of the stomach in the study of malignant lymphomas]. (1973) (0)
- 2203 Association with programmed death ligand-1 (PDL-1) expression and Helicobacter pylori infection in patients with “non diffusive type” gastric carcinoma radically resected (2015) (0)
- Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort (2014) (0)
- Efficacy of Octreotide Long-Acting Repeatable (OCT) From the Phase III RADIANT-2 Study in Patients With Advanced Neuroendocrine Tumors (NET) : A Post-Hoc Analysis of the Placebo (PBO) Arm With Updated Survival Data (2015) (0)
- The Lateral Gastric X-ray Examination in Malignant Lymphomas. (1973) (0)
- MERKEL CELL CARCINOMAAFTER LIVER TRANSPLANTATION: A CASE REPORT (2007) (0)
- Erratum: Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma) (Melanoma Research (1999) 9, (503-509)) (2007) (0)
- [Combined therapy of rectal tumors: the chemotherapy]. (2001) (0)
- Insulin-like growth factor (IGF) components in postmenopausal metastatic breast cancer (MBC) patient having progressed on tamoxifen: different effect of exemestane (EXE) or megestrol acetate (MA) (2001) (0)
- Hormonal-therapy in patients with stage-iv breast-cancer at diagnosis. (1995) (0)
- Combined modality treatment in stage I and II diffuse non-Hodgkin's lymphomas. (1985) (0)
- Efficacy of neoadjuvant toremifene (TOR) and intratumor expression of estrogen receptor (ER) Α and Β in elderly breast cancer (BC) patients. (2004) (0)
- Immunostaining for c-kit (CD117) in well differentiated and poorly differentiated neuroendocrine tumors. (2004) (0)
- Chapter 14 – NON-HODGKIN'S LYMPHOMAS: MILAN STUDIES (1985) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Emilio Bajetta?
Emilio Bajetta is affiliated with the following schools: